FOS and diabetic kidney disease: Multi-faceted bioinformatics analysis coupled with cross-validation revealed that the therapeutic mechanism of AS against DKD involves the targeted inhibition of the MAPK/FOS signaling pathway—associated with podocyte apoptosis—and its mediation of aberrant ECM accumulation.